A ‘nightmare’ at local nursing homes

As of Wednesday, nineteen of New York’s nursing homes have at least 20 coronavirus deaths, a situation being called a ‘nightmare’ by the families of people currently living in the facilities.

No plan in sight: Test troubles cloud Trump recovery effort

But more than a month after President Trump declared, “Anybody who wants a test, can get a test," the reality has been much different. People report being unable to get tested. Labs and public officials say critical supply shortages are making it impossible to increase testing to the levels experts say is necessary to keep the virus in check.

Antibody test limitations

Antibodies in a person's immune system develop to fight COVID-19 and protect them from further infection. But the accuracy of the antibody tests, which were rushed on the market by lab companies in recent weeks, is still in question. Dr. Edward Goldberg has purchased 150 antibody tests that he plans to use on his patients who have either been swabbed or think they may have been infected with the novel coronavirus and recovered. He explains why the tests aren't foolproof yet.

Nursing home deaths soar past 3,300 in alarming surge

More than 2,600 deaths nationwide have been linked to coronavirus outbreaks in nursing homes and long-term care facilities, an alarming rise in just the past two weeks, according to the latest count by The Associated Press.

1st results in on Gilead coronavirus drug; more study needed

More than half of a group of severely ill coronavirus patients improved after receiving an experimental antiviral drug, although there’s no way to know the odds of that happening without the drug because there was no comparison group, doctors reported Friday.

Next potential shortage: Drugs needed to run ventilators

As hospitals scour the country for scarce ventilators to treat critically ill patients stricken by the new coronavirus, pharmacists are beginning to sound an alarm that could become just as urgent: Drugs that go hand in hand with ventilators are running low even as demand is surging.